Knicks fire coach Tom Thibodeau after Eastern Conference finals trip, AP source says
NEW YORK (AP) — The New York Knicks fired coach Tom Thibodeau on Tuesday just days after their first trip to the Eastern Conference finals in 25 years, a person with knowledge of the decision told The Associated Press.
The Knicks were eliminated by the Indiana Pacers with a loss in Game 6 on Saturday night. They then decided to move on from Thibodeau, who led them to the postseason in four of his five seasons in New York.
The decision was made by team president Leon Rose with approval from owner Jim Dolan, the person told the AP on the condition of anonymity because no announcement had been made. The firing was first reported by ESPN.
___
AP NBA: https://apnews.com/nba
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company's OV329 clinical development program. World-leading expert, Dr. Alexander Rotenberg will join company management to discuss the emerging use of a wide range of biomarkers for the study of anti-seizure medicines. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30 to 10:30 am ET and will be webcast simultaneously. Sophisticated imaging and radiological tools are increasingly enabling medicines developers to leverage biomarkers earlier in clinical development to identify signals of biological target engagement and pharmacodynamic activity. Discussion will focus on how these tools drive evidence informed approaches in drug development and provide insight into potential clinical outcomes. Ovid management will describe the exploratory biomarkers in use to measure its next-generation GABA-aminotransferase (GABA-AT) inhibitor program, OV329, which is anticipated to have a topline readout in Q3 2025. Keynote speaker: Leading pediatric neurologist and epileptologist Alexander Rotenberg, M.D., Ph.D. Professor of Neurology at Boston Children's Hospital and Harvard Medical School, and Director of the Epilepsy Monitoring Unit at Boston Children's Hospital, and the Experimental Neurophysiology Core at F.M. Kirby Center of Neurobiology Unfortunately, nearly 40 percent of people living with epilepsy continue to experience seizures despite existing medicines. OV329 is a next-generation GABA-AT inhibitor, that was rationally designed to work differently from current medicines and may offer a novel approach for patients with treatment-resistant seizures. OV329 seeks to endogenously deliver optimal levels of GABA to reduce seizures and provide a preferable safety and tolerability profile relative to the first-generation, GABA-AT inhibitor, vigabatrin. OV329 is currently completing a Phase 1 study that is evaluating its effects on multiple pharmacodynamic biomarkers, safety, tolerability, and pharmacokinetics. Interested in attending or participating remotely: To register, please visit: Registration Link A live webcast of the presentation can be accessed through the Events & Presentations section of Ovid's website at About Ovid Therapeutics Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit Forward-Looking Statements This press release includes certain disclosures by Ovid that contain 'forward-looking statements' including, without limitation: statements regarding the expected timing of initiation, completion, and results and data of Ovid's clinical studies; the potential use and development of OV329, OV350, OV4071 and other compounds from Ovid's library of direct activators of KCC2; and other statements that are not historical fact. You can identify forward-looking statements because they contain words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'may,' 'plan,' 'potentially,' and 'will,' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid's ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its business strategy or unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption 'Risk Factors' in Ovid's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ('SEC'), and in subsequent and future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Media and Investor Relations:Victoria Fort vfort@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
20 minutes ago
- Associated Press
Athletes Abroad Summit Returns to Las Vegas July 8–10, 2025 at the Iconic Bellagio Hotel & Casino
Empowering American pro athletes abroad with tools for legacy, business, and personal growth—this summit is built for players, by players who win. LAS VEGAS, NV, UNITED STATES, June 5, 2025 / / -- The highly anticipated Athletes Abroad Summit returns to Las Vegas this summer, taking place July 8–10, 2025, at the iconic Bellagio Hotel & Casino—a fitting venue for high-impact conversations, global networking, and legacy-driven leadership. Held annually during the NBA Summer League, the Athletes Abroad Summit is the first and only business and personal development conference created exclusively for American athletes pursuing professional careers overseas. Now in its second year, the Summit continues to expand its global impact by bringing together a powerful community of athletes, advisors, and industry innovators. Co-founded by Dr. Tywanna Smith, an award-winning international sports advisor and former professional basketball player, and Sonny Weems, a former NBA player and three-time Chinese Basketball Champion, the Summit was launched to fill a critical gap—providing structure, strategy, and support for athletes navigating the unique challenges of international careers. Featured speakers and session leaders include: - Sonny Weems – With nearly two decades of championship experience across the NBA, EuroLeague, and Chinese Basketball Association, Sonny will lead peer-to-peer player sessions focused on winning on and off the court. - Andrea Durham, CEO of Minority Women in Sports – Advocating for global opportunities for women to play, work, and lead in sports. - Jori Davis, Founder & CEO of WeVolve – Delivering tech-driven tools for contract analysis, salary benchmarking, and agent matchmaking—created by athletes, for athletes. - Eddie Gill, Retired NBA Player – Now a financial advisor, board member of the National Retired Players Association, and analyst for the NBA and Indiana Pacers, Eddie shares key insights on long-term financial strategy and transition planning. Summit partners include: - SEICon – A next-gen sports and entertainment innovation platform. - WeVolve – A consultancy advancing leadership and culture in sports. - UFC – A proud Summit Partner supporting athlete-centered growth and opportunity. With over 10,000 American athletes competing internationally each year, the Athletes Abroad Summit is redefining what it means to win beyond the scoreboard. Through focused sessions on financial literacy, mental wellness, brand development, sports technology, and life after sport, the Summit empowers athletes to expand their global reach, protect their futures, and turn their careers into lasting legacies. Set against the backdrop of the world-famous Bellagio—renowned for its art, elegance, and energy—this year's event is poised to be the most impactful yet. Whether an athlete is actively competing overseas or preparing for their next chapter, the Athletes Abroad Summit is a must-attend experience. Register today at and be part of the global movement redefining athlete leadership——built for players, by players who win. This isn't just another event created for athletes—it's led by them. The Athletes Abroad Summit represents a powerful shift from resources being built for players to being driven by players who win. Every speaker, session, and partnership is shaped by athletes who have competed—and succeeded—on the global stage, offering real-world insights designed to help others do the same. Rachel Dares Rachel Dares PR +1 714-718-9043 email us here Visit us on social media: LinkedIn Instagram Other Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
23 minutes ago
- Yahoo
Former Nets HC Steve Nash praised by Thunder's Shai Gilgeous-Alexander
Former Brooklyn Nets head coach Steve Nash had quite the career in the NBA with what he did as a player after spending 18 years in the league. Nash tried to continue his legacy through coaching in Brooklyn and while that didn't work out in his favor, he still found a way to influence one of the best players in the Association today that hails from Canada. "It would be amazing (to win the championship during his MVP season). Steve, obviously, [he's] the pioneer for Canadian basketball," Oklahoma City Thunder superstar Shai Gilgeous-Alexander said during NBA Finals Media Day on Wednesday. Gilgeous-Alexander and the Thunder are looking to take on the Indiana Pacers in Game 1 of the 2025 NBA Finals on Thursday, but he gave some praise to Nash for what he did, not only for him, but for Canada as well. Advertisement "He started the whole thing, I guess you can say," Gilgeous-Alexander continued. "From the way he plays, to the way he carries himself, to his approach to the game. I learned so much from Steve being a 17-year-old kid in two weeks of time that helped me get here, for sure. The things he's done with Canada basketball in a hole and just push the culture forward, it's been amazing." Gilgeous-Alexander, 26, is not only coming off the first MVP award of his seven-year career, but he is doing that for an Oklahoma City team that is looking like a team that's here to stay thanks to their best players being in their early-to-mid 20's. As of this writing, Gilgeous-Alexander is one of 25 current NBA players in the league right now and he's the second Canadian player on the Thunder along with guard Lugentz Dort. Nash came to America to play college basketball at Santa Clara University and from there, he worked his way into being the 15th overall pick in the 1996 NBA Draft by the Phoenix Suns. Nash also spent his time in the league playing for the Dallas Mavericks and the Los Angeles Lakers before retiring after the conclusion of the 2014-15 campaign. This article originally appeared on Nets Wire: Former Nets HC Steve Nash praised by Thunder's Shai Gilgeous-Alexander
